Stocktoria
Marker Therapeutics, Inc. MRKR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-11-08
Marker Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.5M | $6.6M | $3.3M | $3.5M | $1.2M |
| R&D expense | $11.8M | $13.5M | $10.4M | $12.0M | $27.8M |
| Operating income | -$12.9M | -$11.1M | -$14.6M | -$19.8M | -$39.5M |
| Income tax | -$15,156 | $49,953 | $3,675 | — | — |
| Net income | -$12.2M | -$10.7M | -$8.2M | -$29.9M | -$41.9M |
| EPS (diluted) | $-0.79 | $-1.19 | $-0.94 | $-3.58 | $-5.47 |
| Operating cash flow | -$12.0M | -$10.9M | -$16.4M | -$27.0M | -$27.3M |
| Cash & equivalents | $16.1M | $19.2M | $15.1M | $11.8M | $42.4M |
| Total assets | $19.1M | $22.0M | $17.1M | $34.4M | $68.1M |
| Total liabilities | $2.3M | $3.5M | $3.1M | $14.8M | $24.1M |
| Shareholders' equity | $16.8M | $18.6M | $14.1M | $19.6M | $44.0M |
Source: SEC EDGAR filings · CIK 0001094038 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.